Estimated reading time at 200 wpm: 17 minutes

Clozapine is a unique antipsychotic medication that plays a crucial role in treating severe mental health conditions. It is the only drug proven effective for treatment-resistant schizophrenia, offering hope to patients who have not responded to other treatments. See also: Treatment Resistant Schizophrenia. However, its use comes with strict monitoring requirements due to potential serious side effects, including risks to blood health and the heart.

This article explores clozapine’s licenced and unlicenced uses, its historical development, and the protocols for monitoring its safety. It also highlights key findings from research and real-world cases, such as the Northcott inquest, which brought attention to the importance of cardiac monitoring. By understanding clozapine’s benefits and risks, clinicians can make informed decisions to ensure patient safety and improve outcomes.

Busy clinicians may access the Monash University Guidance now – download is here.

Northcott case and growing awareness of cardiac risks

The death of William Northcott brought national attention to clozapine’s cardiac risks. The inquest concluded that the 39-year-old patient, who had treatment-resistant schizophrenia, died in July 2021 from a sudden cardiac arrhythmia caused by an enlarged heart with left-ventricular hypertrophy. Clozapine and fluoxetine were present at therapeutic levels, and amphetamine was detected at recreational levels. The Coroner noted that clozapine, fluoxetine, and amphetamine are all cardio-toxic drugs and that their combined effect on a background of cardiomyopathy precipitated the fatal arrhythmia. Importantly, William’s enlarged heart and cardiomyopathy were not known during his lifetime [1].

Key concerns and recommendations from the report include:

• Patient education: Evidence suggested that regular repetition of information about clozapine’s side effects and red-flag symptoms is necessary. Devon Partnership NHS Trust set up clozapine clinics where staff ask patients about smoking habits, caffeine intake, bowel movements, hypersalivation, sedation, heartburn, and medication changes. The Coroner emphasised adding questions about recent physical illness, palpitations, chest pain, breathlessness, and dizziness [1].
• Access to specialist clinics: Only 60% of the Trust’s patients attended specialist clozapine clinics; the remaining 40% had blood tests at GP surgeries where staff were often not trained in clozapine side effects. The Coroner considered this a national issue and suggested that patients at GP surgeries may receive inferior monitoring [1].
• Cardiomyopathy detection: The Trust’s guidance focused on myocarditis but less on cardiomyopathies such as left-ventricular hypertrophy. Annual ECGs are required for patients on clozapine; however, ECGs are not diagnostic for cardiomyopathies and may be normal. The Coroner observed that echocardiography, not routinely required in national guidance, could identify cardiomyopathies. Since cardiomyopathies can be asymptomatic, the report called for a national review of monitoring protocols [1].

This case illustrates that cardiac monitoring for clozapine should extend beyond routine ECGs. Clinicians should consider baseline and repeat echocardiography and should educate patients about seeking medical advice for cardiac symptoms.

The Coroner’s Prevention of Future Deaths reports show that fatalities linked to clozapine are typically associated with poor monitoring and system failures rather than intrinsic toxicity. Clozapine is prescribed for treatment‑resistant psychosis because the benefits often outweigh its recognised risks. Coroners emphasise that side‑effects such as constipation, metabolic disturbances and cardiac abnormalities must be anticipated and mitigated. They also note that education, routine blood tests and clear communication pathways reduce these risks. Media analyses that label clozapine as uniquely dangerous overlook the context that other high‑risk medications also have PFDs associated with them and that the central issue is often the quality of care. The Coroner in William Northcott’s case, for example, stressed that clozapine was appropriately prescribed and at therapeutic levels. Interpreting PFD data without considering the underlying systemic factors can therefore give a distorted impression of the medication’s safety profile.

On-licence uses

Clozapine is an atypical antipsychotic that remains the only medication with proven efficacy for treatment-resistant schizophrenia. NICE’s quality standard on psychosis and schizophrenia states that adults whose schizophrenia has not responded adequately to at least two different antipsychotic drugs (one of which must be a non-clozapine second-generation antipsychotic) should be offered clozapine [2]. The specialist pharmacy service notes that clozapine is licensed in the UK for treatment-resistant schizophrenia and may also be used for psychoses occurring during Parkinson’s disease [3]. Because of the risk of agranulocytosis, treatment must be prescribed by a consultant psychiatrist registered with a clozapine monitoring service [3]. UK use therefore remains restricted to patients registered with one of three brand-specific monitoring services (Clozaril®/Clozapine Mylan, Denzapine® or Zaponex®) [3]. Clozapine also has a UK marketing authorisation (SmPC) to reduce the risk of recurrent suicidal behaviour in schizophrenia or schizoaffective disorder; this indication is established in the U.S. but is not widely emphasised in UK guidelines.

Off-licence uses

Off-license prescribing of clozapine is uncommon because of its monitoring requirements. Nonetheless, several international reports describe its use in refractory conditions other than schizophrenia:

Borderline personality disorder (BPD)

An open-label study of 15 in-patients with BPD and psychotic disorder showed symptomatic improvement when treated with clozapine at around 250 mg/day [4]. A case series of 22 female in-patients found that clozapine reduced symptom severity and aggressive incidents, with the greatest improvement seen within the first six months [4]. Individual case reports describe benefits in severe self-mutilation and aggression [4]. These findings support cautious off-label use in severe, treatment-refractory BPD under consultant supervision.

Bipolar disorder

Evidence includes a randomized open-label maintenance trial, two studies of acute manic episodes, and case series in refractory bipolar disorder. A Danish retrospective analysis of 326 patients with bipolar disorder treated with clozapine showed reduced psychiatric hospitalisations, polypharmacy, and self-harm [4]. In China, clozapine is reportedly used more routinely for bipolar disorder [4]. Despite these data, there is no UK license and use remains off-label.

Psychotic depression and major depressive disorder

Cases and small series report symptom improvement in psychotic depression [4]; evidence for non-psychotic depression is sparse [4].

Substance-use disorders

Naturalistic studies suggest that clozapine may reduce cravings for alcohol and illicit drugs in people with schizophrenia. In a study of 151 dual-diagnosis patients, 79% of those on clozapine achieved remission from alcohol use versus 33.7% on other antipsychotics [4]. Evidence is insufficient to support clozapine solely for substance misuse [4].

Suicidality and aggression

The International Suicide Prevention Trial (InterSePT) demonstrated that clozapine reduced recurrent suicidal behaviour in schizophrenia and schizoaffective disorder [4]. Other reports describe reduced aggression in psychotic disorders; clozapine is thought to be superior among atypical antipsychotics for addressing aggression because of its broad dopaminergic and serotonergic activity [4].

Any off-license use should be authorised by the consultant psychiatrist, and UK monitoring services require an off-license treatment agreement [5].

Historical development and niche

1959 — discovery

Clozapine was synthesized during screening of tricyclic compounds by Wander Laboratories in Switzerland and was soon recognised as having neuroleptic properties but an “atypical” profile [6]. Its weak dopamine receptor blockade contradicted the prevailing belief that extrapyramidal symptoms were intrinsic to antipsychotic activity [6].

1970s — early trials and withdrawal

German psychiatrists Stille and Hippius challenged the “neuroleptic dogma” by showing that clozapine’s antipsychotic activity did not depend on extrapyramidal symptoms [6]. However, in 1974 eight Finnish patients died of agranulocytosis while taking clozapine [6]. The drug was withdrawn in many countries and reintroduced only under strict blood-monitoring programs [6].

1980s — rediscovery and trials

Protests from clinicians and relapses in patients who had benefited led to renewed use under controlled conditions [6]. Landmark trials in 1988 demonstrated clozapine’s superiority over chlorpromazine, fluphenazine, and haloperidol in treatment-resistant schizophrenia [6].

1990s — approval and ‘gold standard’

The U.S. Food and Drug Administration approved clozapine for treatment-resistant schizophrenia in 1990. Its low propensity to cause tardive dyskinesia and benefits for negative symptoms, quality of life, and suicide prevention established it as the gold-standard therapy for treatment-resistant schizophrenia [6]. Regular blood monitoring (initially weekly) mitigated the risk of agranulocytosis [6]. These features remain the basis of its restricted niche — clozapine is reserved for patients who have not responded to other antipsychotics but offers significant advantages when tolerated.

Common side effects by SmPC category

The UK Summary of Product Characteristics (SmPC) for Clozaril® categorizes adverse reactions by frequency. The following summary combines SmPC categories with details from the Specialist Pharmacy Service and other sources. The categories (“very common” means ≥1/10, “common” ≥1/100–<1/10, “uncommon” ≥1/1,000–<1/100, “rare” ≥1/10,000–<1/1,000, “very rare” <1/10,000) are those used in SmPCs for UK-licensed medicines.

Monitoring protocols

Blood monitoring schedule

The SmPC mandates regular white blood cell (WBC) and differential counts to mitigate agranulocytosis. UK monitoring services (Clozaril, Denzapine, and Zaponex) implement the following schedule:

• Baseline: Full blood count (FBC) within 10 days before starting clozapine is required to register with a monitoring service.
• Weeks 0–18: WBC and neutrophil counts at least weekly.
• Weeks 19–52: Monitoring every two weeks.
• After 1 year: Monitoring at least every four weeks for the duration of treatment.
• Discontinuation: Monitoring continues for at least four weeks after stopping clozapine.

Results are coded green (continue), amber (increase monitoring), or red (stop clozapine). Clozapine supply is restricted to patients with current green or amber results.

Baseline and routine physical health monitoring

Guidelines from NHS Highland and the Maudsley prescribing group recommend comprehensive baseline assessments before initiating clozapine. Baseline investigations include:

• Laboratory tests: FBC, CRP, fasting glucose, lipid profile, liver function tests (LFTs), urea and electrolytes, troponin I, and pregnancy status.
• Physical tests: Blood pressure, pulse, weight/BMI, smoking status, and bowel function.
• Other: 12-lead ECG and assessment for drug interactions.

Patients must be registered with a clozapine monitoring service before treatment. Initiation is usually in-patient so that orthostatic hypotension, tachycardia, sedation, and seizures can be observed; however, community initiation may occur under specialist supervision.

Monitoring during titration and thereafter

During titration, blood pressure, pulse, temperature, and respiratory rate should be checked daily; side effects and constipation should be actively monitored. Weight, BMI, and waist circumference, fasting glucose, and lipid profile should be assessed at baseline, halfway through titration (around 150 mg), at steady state, and then periodically (e.g., one month, three months, six months, and annually). Plasma clozapine assays may be useful when adverse effects or lack of response occurs.

Cardiac monitoring is a particular focus following the Northcott case:

• The Zaponex summary table recommends baseline ECG and troponin; CRP and troponin should be monitored at least weekly during the first month and then at 3 and 6 months and annually. Echocardiography is recommended at baseline and may be repeated as clinically indicated.
• A recent review of clozapine-induced myocarditis suggests checking CRP, troponin, and eosinophil counts at baseline and weekly for the first eight weeks [10]. Elevated CRP often precedes troponin elevation; troponin levels more than twice the upper limit of normal or CRP levels >100 mg/L warrant cessation of clozapine. Assessment of brain natriuretic peptide (BNP or NT-proBNP) at baseline and during suspected myocarditis may aid diagnosis. This concept is adapted from Monash University’s myocarditis monitoring guidelines [10]. Echocardiography should be performed before initiation and used as the primary monitoring tool if myocarditis is suspected.

Ongoing physical health checks

Patients prescribed clozapine should be on the Severe Mental Illness register, which is maintained by GP practices to identify individuals with schizophrenia, bipolar disorder, or other psychoses for monitoring and improving physical health outcomes. This register is used to track delivery of annual physical health checks, including components like alcohol status, smoking status, BMI, blood pressure, blood glucose, and lipid profile.

Clinicians should discuss smoking status, caffeine intake, bowel habits, hypersalivation, sedation, nausea, urinary symptoms, chest pain, breathlessness, and dizziness at each contact. Tobacco smoking, caffeine, and infection can significantly alter clozapine metabolism; dose adjustments may be needed when these factors change.

Smoking and serum clozapine levels

Tobacco smoking induces CYP1A2, increasing clozapine metabolism and lowering plasma levels. When patients who regularly smoke switch to vaping nicotine, their CYP1A2 enzyme activity decreases. This can lead to higher clozapine levels in the blood, increasing the risk of toxicity. Serum clozapine (and norclozapine) levels should be checked when smoking status changes or when side effects or non-response emerge unexpectedly.

Managing missed doses and toxicity

If more than 48 hours have elapsed since the last dose, the dose should be re-titrated under specialist advice because tolerance to hypotension and tachycardia is lost quickly. Acute toxicity presents with severe sedation, tachycardia, hypotension, hypersalivation, respiratory depression, delirium, and seizures; any signs of toxicity warrant immediate dose review and may necessitate cessation.

Is clozapine dangerous?

The figures reported by some newspapers conflate deaths among people prescribed clozapine with deaths caused by clozapine. The Evening Standard cited a Times investigation which said that the antipsychotic has been linked to “7,000 deaths since it was approved” and that “The Times’ analysis shows an average of more than 400 clozapine‑linked deaths” reported to the Medicines and Healthcare products Regulatory Agency (MHRA) each year for the past decade [11]. A blog from the Centre for Evidence‑Based Medicine summarised the same article, noting that the drug “may be responsible for over 400 deaths a year” and that around 7,000 deaths have been reported since clozapine was licensed in 1990 [12]. These reports were based on MHRA “yellow card” data and the Preventable Deaths Tracker analysis used by The Times.

In practice every death that occurs while a person is taking clozapine is automatically reported to the MHRA, irrespective of its cause, because of the drug’s special monitoring programme. The yellow‑card totals therefore include deaths from unrelated natural causes and do not demonstrate that clozapine causes 400 deaths annually. When researchers audited UK yellow‑card reports of clozapine‑induced gastrointestinal hypomotility between 2018 and 2022 they found 36 fatal reports meeting their criteria; deaths from this complication averaged about four per year [13], a far cry from the hundreds implied by the media. Moreover, the analysis of Prevention of Future Death reports identified only 17 clozapine‑related cases since 2013 [12], and Coroners commonly attributed harm to lapses in monitoring and communication rather than to an intrinsic toxicity of the drug.

The Royal College of Psychiatrists therefore challenged the newspaper narrative, stressing that clozapine is the most effective treatment for treatment‑resistant schizophrenia, that it “is proven to reduce mortality, both from suicide and natural causes“, and that with careful monitoring “the benefits of clozapine treatment will outweigh its risks” [14]. While the deaths highlighted by the press underscore the need for rigorous monitoring and response to side‑effects, the available evidence does not support the claim that clozapine itself kills 400 people a year; rather, it suggests that mismanagement and systemic failings are key factors and that the drug remains life‑saving for many patients.

Summary

Clozapine occupies a narrow but vital niche in psychiatry. Introduced in 1959 and temporarily abandoned after fatal agranulocytosis in the 1970s, it was revived in the late 1980s and is now regarded as the gold-standard therapy for treatment-resistant schizophrenia. UK guidelines license its use only after failure of at least two other antipsychotic drugs; it may also treat psychoses in Parkinson’s disease and has a limited indication for reducing recurrent suicidality. Evidence from small studies suggests potential benefits in severe borderline personality disorder, bipolar disorder, psychotic depression, substance misuse, suicidality, and aggression, but such uses remain off-license and require specialist oversight.

While media reports have suggested clozapine may be responsible for hundreds of deaths annually, this misrepresents the data. The MHRA’s yellow card system automatically reports all deaths in patients taking clozapine regardless of cause, leading to inflated figures that include deaths from unrelated natural causes. Detailed analysis shows that actual deaths directly attributable to clozapine side effects are far fewer—for example, only about four deaths per year from gastrointestinal complications. The Royal College of Psychiatrists emphasises that clozapine is proven to reduce mortality from both suicide and natural causes, and that with proper monitoring, its benefits outweigh its risks for treatment-resistant patients.

Clozapine’s adverse effects span multiple organ systems; serious risks include agranulocytosis, myocarditis, cardiomyopathy, seizures, and gastrointestinal hypomotility. The Northcott inquest highlighted that cardiomyopathy can be missed and urged better patient education and consideration of echocardiography. Mandatory blood monitoring (weekly to four-weekly depending on duration) and comprehensive baseline assessments (including FBC, CRP, troponin, ECG, and metabolic parameters) are essential. Clinicians should remain vigilant for subtle cardiac symptoms and adjust monitoring schedules accordingly.

The lessons from the Northcott inquest underscore the importance of comprehensive cardiac monitoring, including echocardiography, and patient education about cardiac symptoms. Most preventable deaths appear to result from inadequate monitoring and communication rather than inherent drug toxicity. By integrating these recommendations into practice, clinicians can enhance the safety and efficacy of clozapine treatment, ensuring better outcomes for patients with treatment-resistant schizophrenia and other severe mental health conditions.

References

1. judiciary.uk — Judiciary UK
2. nice.org.uk — NICE Guidance
3. sps.nhs.uk — Specialist Pharmacy Service
4. cdn-uat.mdedge.com — MDedge
5. rightdecisions.scot.nhs.uk — Right Decisions NHS
6. psychiatrist.com — Psychiatrist
7. bmj.com — BMJ
8. pubmed.ncbi.nlm.nih.gov — PubMed
9. dovepress.com — DovePress
10. monash.edu — Monash University
11. standard.co.uk — Evening Standard
12. cebm.ox.ac.uk — Centre for Evidence-Based Medicine
13. pmc.ncbi.nlm.nih.gov — PMC NCBI
14. rcpsych.ac.uk — Royal College of Psychiatrists

Easy-read sections

Easy-read summary for patients and relatives

Clozapine is a medicine that helps people with serious mental health problems, like schizophrenia, when other treatments haven’t worked. It can make a big difference, but it needs special care because it can cause serious side effects.